160 related articles for article (PubMed ID: 35869020)
21. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
22. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
23. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
24. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
25. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Boehme V; Zeynalova S; Kloess M; Loeffler M; Kaiser U; Pfreundschuh M; Schmitz N
Ann Oncol; 2007 Jan; 18(1):149-157. PubMed ID: 17018708
[TBL] [Abstract][Full Text] [Related]
26. Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.
Gordon MJ; Duan Z; Zhao H; Nastoupil L; Ng S; Danilov AV; Iyer S; Giordano SH
Leuk Lymphoma; 2023 Dec; 64(14):2258-2268. PubMed ID: 37706491
[TBL] [Abstract][Full Text] [Related]
27. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Pfreundschuh M; Zwick C; Zeynalova S; Dührsen U; Pflüger KH; Vrieling T; Mesters R; Mergenthaler HG; Einsele H; Bentz M; Lengfelder E; Trümper L; Rübe C; Schmitz N; Loeffler M;
Ann Oncol; 2008 Mar; 19(3):545-52. PubMed ID: 18065407
[TBL] [Abstract][Full Text] [Related]
28. Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
Ludvigsen Al-Mashhadi A; Cederleuf H; Kuhr Jensen R; Holm Nielsen T; Bjerregård Pedersen M; Bech Mortensen T; Relander T; Jerkeman M; Ortved Gang A; Kristensen AL; Roost Clausen M; de Nully Brown P; Tang Severinsen M; Jakobsen LH; Ellin F; El-Galaly TC
Am J Hematol; 2023 Mar; 98(3):388-397. PubMed ID: 36588403
[TBL] [Abstract][Full Text] [Related]
29. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
[TBL] [Abstract][Full Text] [Related]
31. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
[TBL] [Abstract][Full Text] [Related]
32. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
Pfreundschuh M; Trümper L; Kloess M; Schmits R; Feller AC; Rübe C; Rudolph C; Reiser M; Hossfeld DK; Eimermacher H; Hasenclever D; Schmitz N; Loeffler M;
Blood; 2004 Aug; 104(3):634-41. PubMed ID: 15016643
[TBL] [Abstract][Full Text] [Related]
33. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
34. "Diffuse Large B-Cell Lymphoma in the Elderly: Real-World Outcomes From a Developing Country".
Jobanputra K; Nayak L; Jain H; Shet T; Epari S; Bonda VNA; Thorat J; Bagal B; Laskar S; Rangarajan V; Agrawal A; Gujral S; Khanna N; Goda JS; Sengar M
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e898-e906. PubMed ID: 35810145
[TBL] [Abstract][Full Text] [Related]
35. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
Ellin F; Landström J; Jerkeman M; Relander T
Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
Dincol D; Buyukcelik A; Dogan M; Akbulut H; Samur M; Demirkazik A; Senler FC; Onur H; Icli F
Med Oncol; 2010 Sep; 27(3):942-5. PubMed ID: 19787462
[TBL] [Abstract][Full Text] [Related]
37. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Schmitz N; Nickelsen M; Ziepert M; Haenel M; Borchmann P; Schmidt C; Viardot A; Bentz M; Peter N; Ehninger G; Doelken G; Ruebe C; Truemper L; Rosenwald A; Pfreundschuh M; Loeffler M; Glass B;
Lancet Oncol; 2012 Dec; 13(12):1250-9. PubMed ID: 23168367
[TBL] [Abstract][Full Text] [Related]
38. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
39. CHOEP-21 chemotherapy for newly diagnosed nodal peripheral T-cell lymphomas (PTCLs) in Maharaj Nakorn Chiang Mai Hospital.
Rattarittamrong E; Norasetthada L; Tantiworawit A; Chai-Adisaksopha C; Nawarawong W
J Med Assoc Thai; 2013 Nov; 96(11):1416-22. PubMed ID: 24428090
[TBL] [Abstract][Full Text] [Related]
40. Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.
Gómez HL; Samanéz C; Campana F; Neciosup SP; Vera L; Casanova L; Leon J; Flores C; de Mendoza FH; Casteñeda CA; Pinto JA; Vallejos CS
Hematol Oncol Stem Cell Ther; 2012; 5(3):152-7. PubMed ID: 23095791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]